Spain Clears Taima Growth to Grow Medical Cannabis for Export

A Spanish startup has won authorization to cultivate medical cannabis under one of Europe’s most tightly controlled licensing regimes, positioning itself to supply Germany and the United Kingdom, the continent’s two largest medical cannabis markets. Taima Growth, based in the Ribera district of Burgos, received its cultivation licence from Spain’s medicines regulator, the Agencia Española de Medicamentos y Productos Sanitarios, or AEMPS, after more than seven years of development.

There is a catch the licence makes plain: Spain still will not let its own patients buy what Taima plans to grow. Domestic medical use is confined to preparations compounded inside hospital pharmacies, and the country’s licensed cultivators produce almost entirely for export.

What the licence actually allows

Before Taima can sell anything, it must complete validation of three production batches that demonstrate the batch-to-batch consistency pharmaceutical buyers demand. Only then can it begin shipping dried cannabis flower to importers in Germany and the UK.

The authorization is also narrower than the headline framing suggests. Industry coverage has cast Taima as Spain’s fourth licensed medical cannabis cultivator, but the regulator’s published register lists roughly twenty active authorizations, sorted into research, production and process-validation categories. Taima sits in the last group, cleared to grow Cannabis sativa to produce the batches needed to validate a manufacturing process for medical use — a stage short of full commercial production.

That conditional structure is the point. AEMPS required Taima to secure signed contracts with licensed importers in its destination countries, assemble a qualified technical team and have compliant facilities in place before it would grant anything, the gates that account for the long wait. Founder and chief executive Mo Alyasini said the process had been difficult but that the company had got there.

A market built for export

The export tilt is written into Spanish law. Spain regulated medicinal cannabis for the first time only with Royal Decree 903/2025, which took effect in October 2025 and restricts domestic access to standardized preparations compounded in hospital pharmacies and prescribed by specialists for a narrow set of conditions — multiple sclerosis spasticity, severe refractory epilepsy, chemotherapy-related nausea and chronic pain that has not responded to other treatment. The decree excludes dried flower for Spanish patients, while explicitly permitting licensed manufacturers to supply that same flower abroad. Spain has quietly grown into one of Europe’s larger medical cannabis producers, with nearly all of that output leaving the country.

The government has signalled no intention of going further. On June 9, 2026, Secretary of State for Health Javier Padilla told a Senate commission that recreational legalization was “not, by any means, in the plans” and that the decree remains the only framework. The rule has drawn fire from the other direction too: Spain’s general pharmacists’ council has taken it to the Supreme Court over the hospital-only dispensing limit, and patient groups have criticized the exclusion of flower and the specialists-only prescribing rule. None of that alters the calculus for a grower like Taima, whose product is bound for export regardless.

Smaller European jurisdictions have learned how unforgiving that export-only model can be: Jersey’s medical cannabis sector only recently turned its first profit after years of export hurdles.

The German and UK hurdle

Germany and the UK anchor the opportunity Taima is chasing, and both lean on imports to meet rising prescription demand. In the UK, medical cannabis imports have roughly doubled as Canadian producers route supply into the market. Germany, the larger market, still draws the bulk of its supply from abroad, with Canadian and Portuguese producers dominant and domestic cultivation covering only a fraction of what patients consume — the strained supply chain that export-oriented growers across Spain, Portugal and Denmark are racing to fill.

Reaching those patients means clearing the quality bar that governs Europe’s medical cannabis trade: EU good manufacturing practice at the processing stage and good agricultural and collection practice in the field. Without that certification, product does not enter German or British pharmacy channels, and that requirement is the main reason a Spanish cultivation licence says little on its own about whether a grower can actually sell into Europe.

Taima is wagering on quality rather than volume. The company says it screened more than 200 sites before choosing an indoor facility where light, temperature, humidity and feeding are automated, capable of three to five harvests a year. It has put more than €3 million into the project, raised from Spanish investors in agriculture, renewable energy and finance, and is targeting about 1,250 kilograms of output a year to start, with ambitions to reach as much as nine tonnes. “Our objective was never to become the biggest producer,” Alyasini said. “We wanted to build one of the highest-quality cultivation platforms in Europe.”

For now, the licence is permission to prove itself, not to sell. Until the three validation batches clear AEMPS review, Taima’s German and British buyers remain contracts on paper rather than shipments.